Drug candidate mHAM 1102 is based on Primecell´s fifteen years experience with cell and tissue products, for example NTC Chondrograft®, which is in phase II/III clinical trial in EU, and extraordinary orthopedics outputs of University hospital Kralovske Vinohrady in Prague.
Cytokine Bioscience is a spin off Primecell´s research labs 4MEDi and NATIC, simillary as a spin off Biohealing(2018).
Primecell research of mHAM for orthopedics was granted by Technology agency of Czech republic, ID Trend1/FW01010339 in 2019.